Pancreatic Cancer: New FDA Program Speeds Up Promising Drug Trials
Hope Emerges in Pancreatic Cancer Fight as Experimental Drug Shrinks Tumors
Debby Orcutt, 69, faced a grim prognosis last year: pancreatic cancer, a disease notoriously difficult to treat. When her doctor hesitated to offer a timeline, Orcutt made a bold decision. “What did I have to lose?” she asked herself, enrolling in a clinical trial for an experimental medication. The results have been remarkable – her tumor has shrunk by 64%.
Orcutt’s experience is fueling a push for faster approval pathways for promising new treatments. The U.S. Food and Drug Administration (FDA) is piloting a new program designed to accelerate the review process for innovative therapies, starting with the drug that has shown such promise for Orcutt.
A Deadly Disease with Limited Options
Pancreatic cancer is a particularly devastating disease. According to the National Cancer Institute, it’s the third leading cause of cancer death in the United States, accounting for approximately 3% of all cancer deaths. The five-year survival rate is a mere 13%, plummeting to 3% when the cancer has spread. These grim statistics haven’t significantly improved in three decades, highlighting the urgent need for new treatment options.
The experimental drug, known as Daraxonrasib, developed by Revolution Medicines, targets a specific genetic mutation found in many pancreatic cancers. This mutation causes a protein to remain constantly “switched on,” driving uncontrolled cell growth. Daraxonrasib aims to block this signal, effectively halting the cancer’s progression.
FDA’s New Accelerated Pathway
The FDA’s new initiative, the “Commissioner’s National Priority Voucher” program, aims to drastically shorten the review timeline for select drugs. Traditionally, a drug review can take a year or more. The FDA hopes to condense this process to just one month for eligible candidates. The program isn’t just focused on cancer; vouchers have also been awarded for potential treatments for infertility, type 1 diabetes, and other serious conditions.
“We’re going into the pipeline, talking to the reviewers and asking them, ‘What could potentially be amazing?’” FDA Commissioner Marty Makary explained in a recent podcast. The agency’s enthusiasm for Daraxonrasib was a key factor in its selection for the accelerated review.
Balancing Speed and Safety
While the prospect of faster access to life-saving drugs is exciting, some experts caution against compromising safety. Dan Kracov, a partner at Arnold & Porter, emphasizes the need for careful monitoring. “It has to be carefully observed to ensure that standards aren’t lowered to the point that patient safety is jeopardized, just to get a product on the market,” he said.
The FDA maintains that it will uphold rigorous standards throughout the process, focusing on streamlining procedures rather than lowering requirements.
Early Results Offer Hope
In a clinical trial involving 83 patients with advanced pancreatic cancer, Daraxonrasib demonstrated significant efficacy. Tumors shrank in 29% of participants, and over 90% showed no tumor growth. The median overall survival rate was 15.6 months – roughly double the typical survival rate for patients receiving standard treatments. Larger, randomized trials are expected next year to confirm these promising findings.
Pranathi Perati, another patient participating in the trial, experienced a remarkable two-year remission thanks to Daraxonrasib, allowing her to witness her son begin his college career. While her cancer has recently returned, she remains hopeful about future treatment options.
“Every year is a bonus,” Perati said.
The potential of Daraxonrasib and similar drugs targeting RAS mutations represents a significant shift in the fight against pancreatic cancer, offering a glimmer of hope for patients and families facing this challenging disease.